



June 22, 2022

Submitted electronically via email

Michelle Halliez
Assistant Vice President Global Labeling Head at Sanofi
Asma Ali
Associate Director, Channel management US Wholesale Trade & Channel Management
55 Corporate Drive
Bridgewater, NJ 08807

Re: Single Product Identifier (NDC) on External Packaging When COVID-19 Vaccine is Commercially Approved

Dear Mses. Halliez and Ali

The National Council for Prescription Drug Programs (NCPDP) is a not-for-profit American National Standards Institute (ANSI) accredited Standards Developer (ASD) consisting of more than 1,500 members who represent drug manufacturers, chain and independent pharmacies, drug wholesalers, insurers, mail order prescription drug companies, claims processors, pharmacy benefit managers, physician services organizations, prescription drug providers, software vendors, telecommunication vendors, service organizations, government agencies and other parties interested in electronic standardization within the pharmacy services sector of the health care industry. NCPDP provides a forum wherein our diverse membership can develop business solutions, including ANSI-accredited standards and guidance for promoting information exchanges related to medications, supplies and services within the healthcare system.

It is NCPDP's understanding the forthcoming COVID-19 vaccine from Sanofi and GlaxoSmithKline may soon receive approval from the Food and Drug Administration (FDA). NCPDP respectfully requests the external packaging of the vaccine contain a single product identifier (i.e., NDC) with the final volume on the label when the commercial product is approved. A single identifier and volume, used for billing purposes, will eliminate potential confusion between pharmacies and payers, supporting ease of claim submission and adjudication and promoting patient safety.

NCPDP thanks you for your consideration of this important matter.

For direct inquiries or questions related to this letter, please contact:

Sandra Garnand
Standards Specialist, Standards Development
NCPDP
standards@ncdpd.org

Sincerely,

A handwritten signature in black ink, appearing to read 'Lee Ann C. Stember'. The signature is fluid and cursive, written over a white background.

Lee Ann C. Stember
President & CEO

National Council for Prescription Drug Programs (NCPDP)
9240 E. Raintree Drive
Scottsdale, AZ 85260

cc:
Alisha Nielsen, Compendia Subject Matter Expert, VP, Two Labs